{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=17", "query": { "intervention": "Arm 2- Dose Expansion", "page": 17 }, "page_size": 10 }, "pagination": { "page": 17, "page_size": 10, "total_count": 405, "total_pages": 41, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=18&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+2-+Dose+Expansion&page=16&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T22:23:21.016Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07392957", "title": "Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "CTX-009", "type": "DRUG" }, { "name": "CTX-471", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2026-06-16", "completion_date": "2031-06-30", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-15T22:23:21.016Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT07392957" }, { "nct_id": "NCT03708328", "title": "A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Metastatic Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Small Cell Lung Cancer (SCLC)", "Esophageal Squamous Cell Carcinoma (ESCC)" ], "interventions": [ { "name": "Lomvastomig", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2018-10-15", "completion_date": "2024-07-09", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-10-15T22:23:21.016Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03708328" }, { "nct_id": "NCT03298516", "title": "A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute" ], "interventions": [ { "name": "DCLL9718S", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2017-11-15", "completion_date": "2019-07-16", "has_results": false, "last_update_posted_date": "2019-11-19", "last_synced_at": "2026-10-15T22:23:21.016Z", "location_count": 5, "location_summary": "Duarte, California • Aurora, Colorado • New Haven, Connecticut + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03298516" }, { "nct_id": "NCT03481816", "title": "Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostatic Neoplasms", "Prostatic Cancer" ], "interventions": [ { "name": "ETBX-071; adenoviral PSA vaccine", "type": "BIOLOGICAL" }, { "name": "ETBX-061; adenoviral MUC1 vaccine", "type": "BIOLOGICAL" }, { "name": "ETBX-051; adenoviral brachyury vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 18, "start_date": "2018-07-24", "completion_date": "2021-03-09", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-10-15T22:23:21.016Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03481816" }, { "nct_id": "NCT02890069", "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma" ], "interventions": [ { "name": "PDR001", "type": "BIOLOGICAL" }, { "name": "LCL161", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Panobinostat", "type": "DRUG" }, { "name": "QBM076", "type": "DRUG" }, { "name": "HDM201", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 298, "start_date": "2016-10-14", "completion_date": "2022-02-22", "has_results": false, "last_update_posted_date": "2023-01-11", "last_synced_at": "2026-10-15T22:23:21.016Z", "location_count": 9, "location_summary": "Santa Monica, California • Baltimore, Maryland • Boston, Massachusetts + 6 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT02890069" }, { "nct_id": "NCT01839955", "title": "Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Non-small Cell Lung Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Non-small Cell Lung Cancer" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "quinacrine dihydrochloride - Escalation dose", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "quinacrine dihydrochloride - Extension dose", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Neelesh Sharma MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2013-09", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2016-10-31", "last_synced_at": "2026-10-15T22:23:21.016Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01839955" }, { "nct_id": "NCT05608252", "title": "VS-6766+Abema+Fulv in Met HR+/HER- BC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Hormone Receptor-positive Breast Cancer", "Hormone Receptor Positive HER-2 Negative Breast Cancer" ], "interventions": [ { "name": "VS-6766", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adrienne G. Waks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2023-02-23", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-15T22:23:21.016Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05608252" }, { "nct_id": "NCT07524855", "title": "A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "JNJ-101684362 (HLD-0117)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 170, "start_date": "2026-04-09", "completion_date": "2029-10-10", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-15T22:23:21.016Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Sarasota, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07524855" }, { "nct_id": "NCT05057715", "title": "huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Serous Ovarian Cancer" ], "interventions": [ { "name": "VCN-01", "type": "BIOLOGICAL" }, { "name": "huCART-meso Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2022-03-02", "completion_date": "2038-09", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-15T22:23:21.016Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05057715" }, { "nct_id": "NCT02680184", "title": "Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "CMP-001", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 199, "start_date": "2016-04-12", "completion_date": "2022-12-06", "has_results": false, "last_update_posted_date": "2025-07-04", "last_synced_at": "2026-10-15T22:23:21.016Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02680184" } ] }